Gene therapy RGX-202 made available for single patients in need

NCT ID NCT07652606

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: REGENXBIO Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program allows eligible patients to receive RGX-202, a gene therapy, on a single-patient basis outside of a clinical trial. It is designed for those with serious conditions who have no other treatment options. Currently, the program is temporarily not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RGX-202 gene therapy
What this could lead to: If successful, this expanded access program could provide a treatment option for individual patients who have no other alternatives.
What could go wrong: This is an expanded access program, not a clinical trial, so there is limited data on safety and effectiveness. The treatment is temporarily unavailable, and results may not apply to other patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

Contacts and locations

Locations

Regenxbio

Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.